Clinical trials: Polymyalgia Rheumatic (PMR)
Polymyalgia Rheumatica, Rheumatoid Arthritis
Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica
The aim of this study is to evaluate a simple and rapid method in order to better define and treat Polymyalgia Rheumatica by measuring levels of muscle achiness and pain with a blood pressure cuff.
- Conditions
- Polymyalgia Rheumatica, Rheumatoid Arthritis, Rheumatic Disease
- Trial name
- NCT00847236
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Lahey Clinic
Systemic Vasculitis, Spondylarthropathies
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
The purpose of HZ-REUMA study is explore vaccine response and protection against shingles (herpes zoster, HZ) after vaccination with two doses of Shingrix in immunosuppressed patients with inflammatory rheumatic diseases (IRD)…
- Conditions
- Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis, Scleroderma
- Trial name
- HZ-REUMA (NCT06763783)
- Testing
- Shingrix, vaccination with 2 doses of Shingrix vaccine
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Region Skane
Polymyalgia Rheumatica
Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease that affects elderly people. It is characterized by pain and morning stiffness in the shoulders, pelvic girdles and neck.
- Trial name
- NCT05542316
- Where
- Belgium
- Volunteers
- 133 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Polymyalgia Rheumatica (PMR)
DNA Methylation in PMR
Polymyalgia Rheumatica (PMR) is treated with corticosteroids; however, long-term treatment is not feasible due to side effects. Withdrawal of corticosteroids causes a subset of patients to relapse, and there is no current way to…
- Trial name
- NCT07748195
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Polymyalgia Rheumatica (PMR)
Study of Tocilizumab to Treat Polymyalgia Rheumatica
This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess the tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients with polymyalgia rheumatica (PMR).
- Trial name
- NCT01396317
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hospital for Special Surgery, New York
Polymyalgia Rheumatica
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
- Trial name
- REPLENISH-EXT (NCT06331312)
- Testing
- Secukinumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
- Trial name
- V-MIRACLE (NCT06766552)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Polymyalgia Rheumatica (PMR)
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease affecting the elderly. The diagnosis is based on established ACR/EULAR classification criteria.
- Trial name
- JADORE-BARI (NCT07279688)
- Testing
- Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet
- Where
- 23 sites in France
- Volunteers
- 140 people
- Sponsor
- University Hospital, Brest
Polymyalgia Rheumatica
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing…
- Trial name
- REDUCE-PMR-2 (NCT05533164)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 174 people
- Sponsor
- Sint Maartenskliniek
Polymyalgia Rheumatica
A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)
This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited.
- Trial name
- NCT06281236
- Testing
- Prednisolone, SPI-62
- Where
- 5 sites in Germany
- Volunteers
- 1 people
- Sponsor
- Sparrow Pharmaceuticals
Adrenal Insufficiency, Polymyalgia Rheumatica (PMR)
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Cortisol, a glucocorticoid (GC) hormone secreted from the adrenal glands, is essential for survival. Cortisol also possesses anti-inflammatory actions and GC formulations (prednisolone) are used to treat many inflammatory…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
- Trial name
- REPLACE (NCT05193396)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Marianne Andersen
Giant Cell Arteritis, Polymyalgia Rheumatic (PMR)
Giant Cell Arteritis - Ways to Precision Medicine
Long-term follow-up of aortal adverse events, as well as glucocortioid-associated adverse events in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT07084480
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Wuerzburg University Hospital
Polymyalgia Rheumatica (PMR)
Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is the most common chronic inflammatory rheumatic disease among the elderly and is characterized by proximal extremity pain and fatigue.
- Trial name
- REMAP PMR (NCT07010484)
- Testing
- PET/MRI, PET/CT with 18-FDG
- Where
- 7 sites in Denmark
- Volunteers
- 149 people
- Sponsor
- Kresten Krarup Keller